Correction to: Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects.

Authors :: Romito, Ilaria
Porru, Manuela
Braghini, Maria Rita
Pompili, Luca
Panera, Nadia
Crudele, Annalisa
Gnani, Daniela
De Stefanis, Cristiano
Scarsella, Marco
Pomella, Silvia
Mortera, Stefano Levi
de Billy, Emmanuel
Conti, Adrian Libenzio
Marzano, Valeria
Putignani, Lorenza
Vinciguerra, Manlio
Balsano, Clara
Pastore, Anna
Rota, Rossella
Tartaglia, Marco
Source :: Journal of Experimental & Clinical Cancer Research (17569966). 1/27/2022, Vol. 41 Issue 1, p1-6. 6p.
Publication Year :: 2022
Abstract: An amendment to this paper has been published and can be accessed via the original article. [ABSTRACT FROM AUTHOR]

Subjects :: *FOCAL adhesion kinase
*KINASE inhibitors
*HEPATOCELLULAR carcinoma
*SORAFENIB
*EPIGENETICS

Full Text Access

Tools